APXZF (Carasent AB (publ)) Research & Development: $0.00 Mil (TTM As of Mar. 2026)


APXZF Carasent AB (publ) APXZF
80 GF Score
Price $0.15
GF Value $0.18
! 3 Warning Signs
View Full Analysis

What is Carasent AB (publ) Research & Development?

Carasent AB (publ) APXZF 80 Research & Development is $0.00 Mil as of Mar. 2026. GuruFocus rates APXZF with a GF Score™ of 80/100 and a GF Value™ of $0.18. The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Carasent AB (publ)'s Research & Development for the three months ended in Mar. 2026 was $0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00 Mil.

Carasent AB (publ)  (OTCPK:APXZF) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Carasent AB (publ) Research & Development Related Terms

Carasent AB (publ) Research & Development Historical Data

* Premium members only.

The historical data trend for Carasent AB (publ)'s Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Carasent AB (publ) Research & Development Chart

Carasent AB (publ) Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Carasent AB (publ) Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
APXZF
80GF Score
Carasent AB (publ) APXZF
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Carasent AB (publ) Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $0.00 Mil mean?
Carasent AB (publ) (APXZF) has a Research & Development of $0.00 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Carasent AB (publ) and its competitors.
Is Carasent AB (publ)'s Research & Development too high?
Carasent AB (publ)'s current Research & Development is $0.00 Mil. Overall, Carasent AB (publ) has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.
How does Carasent AB (publ)'s Research & Development compare to VEEV and BTSG?
Carasent AB (publ)'s Research & Development of $0.00 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Carasent AB (publ) and its competitors. Carasent AB (publ)'s current Research & Development is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carasent AB (publ) stock overvalued right now?
Carasent AB (publ) (APXZF) has a current Research & Development of $0.00 Mil. The stock's GF Value™ is $0.18, compared to a current price of $0.15 — trading 16.7% below its estimated fair value. The current Research & Development is $0.00 Mil. Carasent AB (publ)'s overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Carasent AB (publ) (APXZF), the current Research & Development is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Carasent AB (publ) (APXZF) Overvalued in 2026?

Based on GuruFocus' analysis, Carasent AB (publ) stock appears to be undervalued. The current stock price of $0.15 is trading 16.7% below its estimated GF Value™ of $0.18.

Key valuation signals for APXZF:

  • Research & Development: $0.00 Mil
  • GF Value™: $0.18 vs. price of $0.15 (16.7% below fair value)
  • GF Score™: 80/100 with 3 warning signs

No single metric tells the full story. See the APXZF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Carasent AB (publ) Business Description

Other Exchanges CARA:SwedenE0C:Germany
Address Nellickevagen 24C, Gothenburg, NOR, 412 63
Carasent AB (publ) Formerly Carasent AB is a comprehensive provider of cloudbased EHR solutions and platform services for various organizations within the healthcare sector. With Webdoc as the main product, the group offers a broad ecosystem of services, including solutions for patient communication and business intelligence. Geographically, the company operates in the Nordic region and Germany. It derives maximum revenue from Nordic Region. The solutions provides by the group are: Webdoc; Metodika; Medrave; HPI plustoo; Ad Curis; Ad Opus; Webcur; Data-AL; and Data-Cur.
80GF Score

Get the complete analysis for APXZF

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.15
Price
$0.18
GF Value